A pilot study of dronabinol for the treatment of pain in sickle cell disease
In conclusion, a controlled study of dronabinol is acceptable, feasible, and safe to participants. However, a crossover design compromises participant masking. A larger, longer, controlled efficacy study without the crossover component is now being performed (NCT05519111). Trial registration NCT03978156. Date of registration: 07/26/2019.
Authors
- Susanna A. Curtis (ORCID: https://orcid.org/0000-0002-2281-0843)
- Sarah McCuskee (ORCID: https://orcid.org/0000-0002-7489-9894)
- John D. Roberts (ORCID: https://orcid.org/0000-0003-2020-6201)
- Jordan Bellis
- Ritika Jhawar
Institutions
- Yale University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Pilot and Feasibility Studies
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1186/s40814-025-01705-6
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00